
Celgene
North America, New Jersey, United States, Summit
Description
Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases.
Investor Profile
Celgene has backed more than 64 startups, with 0 new investments in the last 12 months alone. The firm has led 16 rounds, about 25% of its total and boasts 31 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series A, Series C rounds (top funding stages).
- Majority of deals are located in United States, Canada, China.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
Stage Focus
- Series B (41%)
- Series A (22%)
- Series C (11%)
- Series Unknown (11%)
- Series D (6%)
- Private Equity (3%)
- Post Ipo Equity (3%)
- Series E (2%)
- Corporate Round (2%)
Country Focus
- United States (89%)
- Canada (3%)
- China (2%)
- Switzerland (2%)
- Israel (2%)
- United Kingdom (2%)
- Germany (2%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Pharmaceutical
- Biopharma
- Oncology
- Health Diagnostics
- Medical Device
- Genetics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
Who does Celgene frequently co-invest with?
Which angels does Celgene often collaborate with?
What are some of recent deals done by Celgene?
Find More Investors Like Celgene
Discover similar investors in our database and build your perfect investor list.
Need help with your fundraising strategy?Read our fundraising guides













